NCT03061006View on ClinicalTrials.gov

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

PHASE4CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

April 3, 2017

Primary Completion Date

March 15, 2021

Study Completion Date

March 15, 2021

Conditions
DementiaCognition DisordersCerebral Ischemic Events
Interventions
DRUG

Dabigatran Etexilate

150 mg BID (CrCL \> 30 mL/min) or 75 mg BID (CrCL \> 15 to 30 mL/min); Assessment of kidney function every 6 months.

DRUG

Warfarin

Dose-adjusted (INR 2.0 - 3.0); Standard warfarin follow-up and education based upon system criteria.

Trial Locations (1)

84143

Intermountain Heart Institute, Murray

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Intermountain Health Care, Inc.

OTHER